Updated response assessment criteria for high-grade gliomas

Response assessment in neuro-oncology working group

Patrick Y. Wen, David R. Macdonald, David A. Reardon, Timothy F. Cloughesy, A. Gregory Sorensen, Evanthia Galanis, John DeGroot, Wolfgang Wick, Mark R. Gilbert, Andrew B. Lassman, Christina Tsien, Tom Mikkelsen, Eric T. Wong, Marc C. Chamberlain, Roger Stupp, Kathleen R. Lamborn, Michael A. Vogelbaum, Martin J. Van Den Bent, Susan M. Chang

Research output: Contribution to journalArticle

1766 Citations (Scopus)

Abstract

Currently, the most widely used criteria for assessing response to therapy in high-grade gliomas are based on two-dimensional tumor measurements on computed tomography (CT) or magnetic resonance imaging (MRI), in conjunction with clinical assessment and corticosteroid dose (the Macdonald Criteria). It is increasingly apparent that there are significant limitations to these criteria, which only address the contrast-enhancing component of the tumor. For example, chemoradiotherapy for newly diagnosed glioblastomas results in transient increase in tumor enhancement (pseudoprogression) in 20% to 30% of patients, which is difficult to differentiate from true tumor progression. Antiangiogenic agents produce high radiographic response rates, as defined by a rapid decrease in contrast enhancement on CT/MRI that occurs within days of initiation of treatment and that is partly a result of reduced vascular permeability to contrast agents rather than a true antitumor effect. In addition, a subset of patients treated with antiangiogenic agents develop tumor recurrence characterized by an increase in the nonenhancing component depicted on T2-weighted/fluid-attenuated inversion recovery sequences. The recognition that contrast enhancement is nonspecific and may not always be a true surrogate of tumor response and the need to account for the nonenhancing component of the tumor mandate that new criteria be developed and validated to permit accurate assessment of the efficacy of novel therapies. The Response Assessment in Neuro-Oncology Working Group is an international effort to develop new standardized response criteria for clinical trials in brain tumors. In this proposal, we present the recommendations for updated response criteria for high-grade gliomas.

Original languageEnglish (US)
Pages (from-to)1963-1972
Number of pages10
JournalJournal of Clinical Oncology
Volume28
Issue number11
DOIs
StatePublished - Apr 10 2010

Fingerprint

Glioma
Neoplasms
Angiogenesis Inhibitors
Tomography
Magnetic Resonance Imaging
Sequence Inversion
Capillary Permeability
Chemoradiotherapy
Glioblastoma
Brain Neoplasms
Contrast Media
Adrenal Cortex Hormones
Therapeutics
Clinical Trials
Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., ... Chang, S. M. (2010). Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. Journal of Clinical Oncology, 28(11), 1963-1972. https://doi.org/10.1200/JCO.2009.26.3541

Updated response assessment criteria for high-grade gliomas : Response assessment in neuro-oncology working group. / Wen, Patrick Y.; Macdonald, David R.; Reardon, David A.; Cloughesy, Timothy F.; Sorensen, A. Gregory; Galanis, Evanthia; DeGroot, John; Wick, Wolfgang; Gilbert, Mark R.; Lassman, Andrew B.; Tsien, Christina; Mikkelsen, Tom; Wong, Eric T.; Chamberlain, Marc C.; Stupp, Roger; Lamborn, Kathleen R.; Vogelbaum, Michael A.; Van Den Bent, Martin J.; Chang, Susan M.

In: Journal of Clinical Oncology, Vol. 28, No. 11, 10.04.2010, p. 1963-1972.

Research output: Contribution to journalArticle

Wen, PY, Macdonald, DR, Reardon, DA, Cloughesy, TF, Sorensen, AG, Galanis, E, DeGroot, J, Wick, W, Gilbert, MR, Lassman, AB, Tsien, C, Mikkelsen, T, Wong, ET, Chamberlain, MC, Stupp, R, Lamborn, KR, Vogelbaum, MA, Van Den Bent, MJ & Chang, SM 2010, 'Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group', Journal of Clinical Oncology, vol. 28, no. 11, pp. 1963-1972. https://doi.org/10.1200/JCO.2009.26.3541
Wen, Patrick Y. ; Macdonald, David R. ; Reardon, David A. ; Cloughesy, Timothy F. ; Sorensen, A. Gregory ; Galanis, Evanthia ; DeGroot, John ; Wick, Wolfgang ; Gilbert, Mark R. ; Lassman, Andrew B. ; Tsien, Christina ; Mikkelsen, Tom ; Wong, Eric T. ; Chamberlain, Marc C. ; Stupp, Roger ; Lamborn, Kathleen R. ; Vogelbaum, Michael A. ; Van Den Bent, Martin J. ; Chang, Susan M. / Updated response assessment criteria for high-grade gliomas : Response assessment in neuro-oncology working group. In: Journal of Clinical Oncology. 2010 ; Vol. 28, No. 11. pp. 1963-1972.
@article{ea15942129934749a22259d91132b14d,
title = "Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group",
abstract = "Currently, the most widely used criteria for assessing response to therapy in high-grade gliomas are based on two-dimensional tumor measurements on computed tomography (CT) or magnetic resonance imaging (MRI), in conjunction with clinical assessment and corticosteroid dose (the Macdonald Criteria). It is increasingly apparent that there are significant limitations to these criteria, which only address the contrast-enhancing component of the tumor. For example, chemoradiotherapy for newly diagnosed glioblastomas results in transient increase in tumor enhancement (pseudoprogression) in 20{\%} to 30{\%} of patients, which is difficult to differentiate from true tumor progression. Antiangiogenic agents produce high radiographic response rates, as defined by a rapid decrease in contrast enhancement on CT/MRI that occurs within days of initiation of treatment and that is partly a result of reduced vascular permeability to contrast agents rather than a true antitumor effect. In addition, a subset of patients treated with antiangiogenic agents develop tumor recurrence characterized by an increase in the nonenhancing component depicted on T2-weighted/fluid-attenuated inversion recovery sequences. The recognition that contrast enhancement is nonspecific and may not always be a true surrogate of tumor response and the need to account for the nonenhancing component of the tumor mandate that new criteria be developed and validated to permit accurate assessment of the efficacy of novel therapies. The Response Assessment in Neuro-Oncology Working Group is an international effort to develop new standardized response criteria for clinical trials in brain tumors. In this proposal, we present the recommendations for updated response criteria for high-grade gliomas.",
author = "Wen, {Patrick Y.} and Macdonald, {David R.} and Reardon, {David A.} and Cloughesy, {Timothy F.} and Sorensen, {A. Gregory} and Evanthia Galanis and John DeGroot and Wolfgang Wick and Gilbert, {Mark R.} and Lassman, {Andrew B.} and Christina Tsien and Tom Mikkelsen and Wong, {Eric T.} and Chamberlain, {Marc C.} and Roger Stupp and Lamborn, {Kathleen R.} and Vogelbaum, {Michael A.} and {Van Den Bent}, {Martin J.} and Chang, {Susan M.}",
year = "2010",
month = "4",
day = "10",
doi = "10.1200/JCO.2009.26.3541",
language = "English (US)",
volume = "28",
pages = "1963--1972",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - Updated response assessment criteria for high-grade gliomas

T2 - Response assessment in neuro-oncology working group

AU - Wen, Patrick Y.

AU - Macdonald, David R.

AU - Reardon, David A.

AU - Cloughesy, Timothy F.

AU - Sorensen, A. Gregory

AU - Galanis, Evanthia

AU - DeGroot, John

AU - Wick, Wolfgang

AU - Gilbert, Mark R.

AU - Lassman, Andrew B.

AU - Tsien, Christina

AU - Mikkelsen, Tom

AU - Wong, Eric T.

AU - Chamberlain, Marc C.

AU - Stupp, Roger

AU - Lamborn, Kathleen R.

AU - Vogelbaum, Michael A.

AU - Van Den Bent, Martin J.

AU - Chang, Susan M.

PY - 2010/4/10

Y1 - 2010/4/10

N2 - Currently, the most widely used criteria for assessing response to therapy in high-grade gliomas are based on two-dimensional tumor measurements on computed tomography (CT) or magnetic resonance imaging (MRI), in conjunction with clinical assessment and corticosteroid dose (the Macdonald Criteria). It is increasingly apparent that there are significant limitations to these criteria, which only address the contrast-enhancing component of the tumor. For example, chemoradiotherapy for newly diagnosed glioblastomas results in transient increase in tumor enhancement (pseudoprogression) in 20% to 30% of patients, which is difficult to differentiate from true tumor progression. Antiangiogenic agents produce high radiographic response rates, as defined by a rapid decrease in contrast enhancement on CT/MRI that occurs within days of initiation of treatment and that is partly a result of reduced vascular permeability to contrast agents rather than a true antitumor effect. In addition, a subset of patients treated with antiangiogenic agents develop tumor recurrence characterized by an increase in the nonenhancing component depicted on T2-weighted/fluid-attenuated inversion recovery sequences. The recognition that contrast enhancement is nonspecific and may not always be a true surrogate of tumor response and the need to account for the nonenhancing component of the tumor mandate that new criteria be developed and validated to permit accurate assessment of the efficacy of novel therapies. The Response Assessment in Neuro-Oncology Working Group is an international effort to develop new standardized response criteria for clinical trials in brain tumors. In this proposal, we present the recommendations for updated response criteria for high-grade gliomas.

AB - Currently, the most widely used criteria for assessing response to therapy in high-grade gliomas are based on two-dimensional tumor measurements on computed tomography (CT) or magnetic resonance imaging (MRI), in conjunction with clinical assessment and corticosteroid dose (the Macdonald Criteria). It is increasingly apparent that there are significant limitations to these criteria, which only address the contrast-enhancing component of the tumor. For example, chemoradiotherapy for newly diagnosed glioblastomas results in transient increase in tumor enhancement (pseudoprogression) in 20% to 30% of patients, which is difficult to differentiate from true tumor progression. Antiangiogenic agents produce high radiographic response rates, as defined by a rapid decrease in contrast enhancement on CT/MRI that occurs within days of initiation of treatment and that is partly a result of reduced vascular permeability to contrast agents rather than a true antitumor effect. In addition, a subset of patients treated with antiangiogenic agents develop tumor recurrence characterized by an increase in the nonenhancing component depicted on T2-weighted/fluid-attenuated inversion recovery sequences. The recognition that contrast enhancement is nonspecific and may not always be a true surrogate of tumor response and the need to account for the nonenhancing component of the tumor mandate that new criteria be developed and validated to permit accurate assessment of the efficacy of novel therapies. The Response Assessment in Neuro-Oncology Working Group is an international effort to develop new standardized response criteria for clinical trials in brain tumors. In this proposal, we present the recommendations for updated response criteria for high-grade gliomas.

UR - http://www.scopus.com/inward/record.url?scp=77951625266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951625266&partnerID=8YFLogxK

U2 - 10.1200/JCO.2009.26.3541

DO - 10.1200/JCO.2009.26.3541

M3 - Article

VL - 28

SP - 1963

EP - 1972

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -